Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes

Patent metadata

Field	Value
Publication number	US-10688202-B2
Application number	US-201515329876-A
Country	US
Kind code	B2
Filing date	Jul 28, 2015
Priority date	Jul 28, 2014
Publication date	Jun 23, 2020
Grant date	Jun 23, 2020

Abstract

The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.

First claim

What is claimed is:

1. A method of preparing medical isotope labeled metal(loid) chalcogen nanoparticles, the method comprising steps of:
supplying a reaction mixture comprising:
metal(loid) chalcogen nanoparticles selected from the group consisting of metalloid chalcogen nanoparticles and metal(loid) chalcogen-coated metal nanoparticles, and
medical isotopes selected from the group consisting of PET-active radioisotopes, SPECT-active radioisotopes, MRI-active metals, and therapeutic radioisotopes,
which reaction mixture is substantially free of chelator; and

maintaining the reaction mixture under conditions and for a time sufficient for the medical isotopes to directly bind to the metal(loid) chalcogen nanoparticles, thereby forming the medical isotope labeled metal(loid) chalcogen nanoparticles
wherein the conditions comprise heating the reaction mixture to a temperature of equal to or greater than 25° C.

2. The method of claim 1 , further comprising a step of isolating the medical isotope labeled metal(loid) chalcogen nanoparticles.

3. The method of claim 2 , wherein the step of isolating the medical isotope labeled metal(loid) chalcogen nanoparticles comprises centrifuging the reaction mixture or filtrating the reaction mixture.

4. The method of claim 2 , further comprising dispersing the isolated medical isotope labeled metal(loid) chalcogen nanoparticles in an infusion fluid.

5. The method of claim 1 , wherein the time is between 5 and 120 minutes.

6. The method of claim 1 , further comprising administering the medical isotope labeled metal(loid) chalcogen nanoparticles to a subject in vivo.

7. The method of claim 1 , wherein integrity of the medical isotope labeled metal(loid) chalcogen nanoparticles is not affected by the steps.

8. The method of claim 1 , wherein the metal(loid) chalcogen nanoparticles are doped with a fluorescent agent.

9. The method of claim 1 , wherein the metal(loid) chalcogen nanoparticles are doped with a metal or a semi-metal.

10. The method of claim 1 , wherein the metal(loid) chalcogen nanoparticles are doped with a non-metal.

11. The method of claim 1 , wherein the metal(loid) chalcogen nanoparticles are doped with a combination of at least two materials selected from the list consisting of fluorescence agents, metals, semi-metals, and non-metals.

12. The method of claim 1 , wherein binding between the metal(loid) chalcogen nanoparticles and the medical isotope is covalent.

13. The method of claim 1 , wherein binding between the metal(loid) chalcogen nanoparticles and the medical isotope is non-covalent.

14. The method of claim 13 , wherein binding between the metal(loid) chalcogen nanoparticles and the medical isotope is via chelate bonds.

15. The method of claim 1 , wherein the metal(loid) chalcogen nanoparticles have a longest dimension between 2-1000 nm.

16. The method of claim 1 , wherein the conditions comprise heating the reaction mixture to a temperature of between 45° C. and 80° C.

17. The method of claim 1 , wherein the conditions comprise heating the reaction mixture to a temperature of equal to or greater than 95° C.

18. The method of claim 15 , wherein the metal(loid) chalcogen nanoparticles have a longest dimension between 2-800 nm.

19. The method of claim 15 , wherein the metal(loid) chalcogen nanoparticles have a longest dimension between 2-500 nm.

20. The method of claim 15 , wherein the metal(loid) chalcogen nanoparticles have a longest dimension between 2-200 nm.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Wall Matthew A
• Shaffer Travis
• Harmsen Stefan
• Grimm Jan
• Kircher Moritz F

Classifications

• A61K51/1251 Primary

  micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules · CPC title

• B82Y15/00

  Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors · CPC title

• A61K51/1244 Primary

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61K51/025

  inorganic Tc complexes or compounds · CPC title

• A61P35/00

  Antineoplastic agents · CPC title